drugset
Drugs / Meningococcal MenACWY Conjugate Vaccine
last change Nov 2023 re-read 2 minutes ago

Meningococcal MenACWY Conjugate Vaccine

also known as GSK3536820A · MenA lyo + MenCWY liquid

Vaccine

Developed for
meningococcal infection
Investigated by
GlaxoSmithKline

Trials 1 · a red edge is where a trial was stopped

today NCT04318548 · Ph 3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT04318548 Aug 2020 → Nov 2023 meningococcal infection GlaxoSmithKline Completed No outcome recorded

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Meningococcal MenACWY Conjugate Vaccine ClinicalTrials.gov intervention name — accepted as the source's own label NCT04318548 ↗
Known as GSK3536820A “Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)” NCT04318548 ↗
Known as MenA lyo + MenCWY liquid “Meningococcal MenACWY Conjugate Vaccine (GSK3536820A) (MenA lyo + MenCWY liquid)” NCT04318548 ↗
Modality Vaccine “Meningococcal MenACWY Conjugate Vaccine” NCT04318548 ↗
Route Intramuscular “MenACWY administered intramuscularly” NCT04318548 ↗